drugset / Trial / NCT06432764

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

NCT06432764 ↗

Phase 1 Completed 9 enrolled AstraZeneca
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to measure the changes in intestinal uptake of radioligand \[11C\]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.

Timeline

Start
2024-10-16
Primary completion
2026-03-27
Completion
2026-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7798 Unknown — —

Indications